Heders- och gästföreläsare

Pernilla Lagergren

Professor vid Karolinska Institutet och Imperial College London

Hedersföreläsning Sjuksköterskor i Cancervård

Pernilla Lagergren är professor i kirurgisk vårdvetenskap vid Karolinska Institutet och innehar även en professur på deltid vid Imperial College London. Hon är legitimerad sjuksköterska och har en bakgrund inom kirurgisk och onkologisk vård, där hon under flera år arbetade kliniskt som kontaktsjuksköterska med patienter som diagnostiserats med matstrups- eller magsäckscancer. Efter sin disputation 2006 har hon fortsatt med forskning på heltid. Hennes forskning fokuserar främst på livskvalitet, patientrapporterade utfallsmått (PROMs) och personcentrerad vård efter kirurgisk behandling av cancer, särskilt matstrups- och magsäckscancer. Pernilla leder och är delaktig i flera projekt, har publicerat över 200 vetenskapliga artiklar inom sitt fält och huvudhandlett tio doktorander till disputation. Hon har fått flertalet priser för sina forskningsinsatser, bland annat Anders Jahre’s Nordiska pris till yngre medicinska forskare 2015 och Hilda och Alfred Erikssons forskningspris från Kungliga Vetenskapsakademien 2020. Pernilla är även en stark förespråkare för att integrera patientens perspektiv i forskning genom nära samarbeten med patienterfarna och närstående.

Roger Stupp

Paul C. Bucy Professor of Neurological Surgery Professor of Medicine (Hematology/Oncology) and Neurology, Northwestern University Feinberg School of Medicine. Medical Director, Northwestern Medicine Lou & Jean Malnati Brain Tumor Institute; Associate Director, Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, Illinois

Hedersföreläsning Acta Oncologica

Dr. Roger Stupp is an internationally recognized medical- and neuro-oncologist and a leading authority on primary and metastatic brain cancer. His interest is drug development, innovative cancer treatments and trial design. Dr. Stupp has been the lead investigator for numerous clinical trials from first-in-human phase 1 to pivotal phase 3 registration studies. Drs. Stupp and Hegi published in the New England Journal of Medicine two landmark papers on the use of temozolomide in conjunction with radiation for newly diagnosed glioblastoma and demonstrated that silencing of the DNA repair enzyme MGMT predicts response to therapy and prolonged survival. These publications established a new treatment paradigm for primary brain tumors that remains the strategic backbone of most treatment protocols. Dr. Stupp also developed the trials establishing Tumor Treating Fields – alternating electrical fields that are delivered continuously through a portable battery-powered device – as a new cancer treatment modality for GBM, now also shown effective in brain metastases, lung and pancreas cancer. Ongoing work focuses on opening the blood-brain barrier with ultrasound (with Adam Sonabend, MD) allowing the use of novel cancer drugs for the treatment of brain cancer. Surrounded by a large team of top-notch researchers of the Malnati Brain Tumor Institute at Northwestern University in Chicago, he and the translational research teams are pushing the boundaries by combining latest diagnostic and therapeutic technologies, integration of immunotherapy and novel drugs into a multimodality treatment, and rigorously evaluating new agents or technologies in clinical trials with innovative designs The ultimate goal is to improve outcome and quality of life for patients suffering from brain tumors.

Dr. Stupp served as secretary to the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group from 2002 – 2008, and on the EORTC Board of Directors from 2006 – 2017, from 2012 -2017 as its president.

Anne Katz

PhD, RN, University of Manitoba, Canada

Cancer and sexuality: important or novelty topic?

Dr. Anne Katz is a certified sexuality counselor and registered nurse. With a PhD in nursing and certification in human sexuality, she has become a pioneer in addressing the often-overlooked intersection of sexual health and cancer survivorship. Dr. Katz’s career reflects a deeply human-centered approach, fostering dialogue, validation, and healing for cancer survivors and their partners as they reclaim sexual intimacy and quality of life.
Dr. Katz has authored over a dozen books—targeted both toward health professionals and patients—dealing with sexuality, illness, and survivorship. Her seminal work, Breaking the Silence on Cancer and Sexuality, became the first comprehensive textbook in the field and remains influential among clinicians. She later published consumer-focused titles including Woman Cancer Sex, Man Cancer Sex, and Prostate Cancer and the Man You Love. Several of her books have won major awards, including the SSTAR Consumer Book Award in 2015 and 2023 and a Prose Award for psychosocial care for young adults with cancer. She served for 8 years as the editor of the Oncology Nursing Forum, the premier research journal of the Oncology Nursing Society.

Professor Charles Swanton

MBPhD, FRCP, FMedSci, FAACR, FRS

Hedersföreläsning Jan Waldenström

Charles completed his MBPhD training in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. He is a senior Principal Investigator of the Cancer Evolution and Genome Instability Laboratory, and Deputy clinical director at the Francis Crick Institute. He combines his research with clinical duties at UCLH as a Consultant thoracic oncologist, focused on how tumours evolve over space and time. His research branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome. Charles is chief investigator of TRACERx, a lung cancer evolutionary study, the national PEACE autopsy program, and the TRACERx EVO study.

Charles was made Fellow of the Royal College of Physicians in April 2011, appointed Fellow of the Academy of Medical Sciences in 2015, awarded the Royal Society Napier Professorship in Cancer in 2016, appointed Cancer Research UK’s Chief Clinician in 2017, elected Fellow of the Royal Society in 2018, Fellow of the Academy of the American Association for Cancer Research in 2020, and appointed Deputy Clinical Director of the Francis Crick Institute in 2023. He is an editorial board member of Cell, Plos Medicine, Cancer Discovery and Annals of Oncology and an advisory board member for Nature Reviews Clinical Oncology and Cancer Cell. In 2016 he co-founded Achilles Therapeutics, a UCL/CRUK/Francis Crick Institute spin-out company, assessing the efficacy of T cells targeting clonal neoantigens.

Charles has been awarded several prizes including the Stand up to Cancer Translational Cancer Research Prize (2015), GlaxoSmithkline Biochemical Society Prize (2016), San Salvatore prize for Cancer Research (2017) and the Ellison-Cliffe Medal, Royal Society of Medicine (2017), recipient of the Gordon Hamilton Fairley Medal (2018), Massachusetts General Hospital, Jonathan Kraft Prize for Excellence in Cancer Research (May 2018), the ESMO Award for Translational Cancer Research (2019), Addario Lung Cancer Foundation Award and Lectureship, International Lung Cancer Congress (July 2020), the Weizmann Institute Sergio Lombroso Award in Cancer Research (2021), International Society of Liquid Biopsy (ISLB) Research Award (2021), the Memorial Sloan Kettering Paul Marks Prize for Cancer Research (2021), UCLH Celebrating Excellence Award for Contribution to World Class Research (2022), Inductee to OncLive’s Giants of Cancer Care awards program (2023), SpringerNature CDD Award (2023), the Jeantet-Collen Prize for Translational Medicine (2024), and the Gustave Roussy Prize (2025). In 2025, he was elected as a member of the U.S. National Academy of Medicine, recognising his contributions to understanding tumour evolution and advancing translational cancer research.

Peter Hoskin

Professor
Hedersföreläsning Berven

Professor Peter Hoskin has been a pioneer in British and European radiotherapy. His research spans from biomarkers, radiosensitizers, palliative radiotherapy, brachytherapy and stereotactic body radiotherapy. He has been awarded the Marie Curie medal in 2024, and the Emmanuel van der Schueren Award (by ESTRO) in 2022. It is with great pleasure we welcome him to hold the Elis Berven lecture in Sweden!